[Skip to Navigation]
Sign In
December 1, 2004

Postmarketing Surveillance—Lack of Vigilance, Lack of Trust

Author Affiliations

Author Affiliations: Dr Fontanarosa is Executive Deputy Editor, Dr Rennie is Deputy Editor, and Dr DeAngelis is Editor-in-Chief, JAMA.


Published online November 22, 2004 (doi:10.1001/jama.292.21.2647).

JAMA. 2004;292(21):2647-2650. doi:10.1001/jama.292.21.2647

Physicians and patients expect that when medications are prescribed correctly for labeled indications and are used as directed, these medications generally will have beneficial effects and will not cause significant harm. This confidence in pharmaceutical products reflects trust in the effectiveness and integrity of the drug approval and monitoring process.

However, the current approval process for drugs and biological agents in the United States has come under intense scrutiny, most notably because of concerns about influence from industry. For instance, since adoption of the 1992 Prescription Drug User Fee Act, which augmented the budget of the Food and Drug Administration (FDA) by charging “user fees” to pharmaceutical firms,1 the FDA has received approximately $825 million in fees from drug and biologic manufacturers from fiscal years 1993 through 2001.2,3 During that time, median approval times for standard (ie, “nonpriority”) drugs decreased from 27 months in 1993 to 14 months in 2001, but as an inevitable consequence of faster approvals, drug recalls following approval increased from 1.56% for 1993-1996 to 5.35% for 1997-2001.2 In addition, an investigation of 18 FDA expert advisory panels revealed that more than half of the members of these panels had direct financial interests in the drug or topic they were evaluating and for which they were making recommendations.4

Add or change institution